Anchored in technology licensed from the University of Michigan, with facilites in Michigan and Pennsylvabia, Opsidio, LLC, is a biotech company engaged in developing anti-fibrotic monoclonal antibodies to treat fibrotic and remodeling diseases such as Idiopathic Pulmonary Fibrosis, Chronic Kidney Disease, Systemic Sclerosis and severe asthma. The antibodies work at the top of the cascade of events that cause disease, and have been highly effective in several preclinical models.
